TB-500 Compounding Legal Status: FDA Approval, Safety, and What Patients Need to Know
See the public record for TB-500
At a glance
- FDA approval / Not an FDA-approved drug [1]
- What it is / Synthetic 7-amino-acid fragment of thymosin beta-4 [1]
- Compounding list status / Not on FDA's bulks list for state-licensed pharmacies or outsourcing facilities [2][3][4]
- Category 1 policy / Does not cover TB-500 [2][3][4]
- Advisory committee / Voted in favor of listing on July 23, 2026; advice only [5][6]
- HHS draft policy / Non-binding enforcement discretion for TB-500 acetate injection, not approval [6][7]
- Key safety concern / Injection may carry an immune-reaction risk from aggregation and peptide impurities [1][8]
- Sport / WADA prohibits thymosin-beta4 and derivatives including TB-500 at all times [9]
Is TB-500 FDA-approved?
No. TB-500 is not an FDA-approved drug. FDA's July 2026 review found no USP or National Formulary monograph for it, no FDA-approved drug containing it, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy or authorized by the European Medicines Agency [1].
What is TB-500?
TB-500 is a synthetic 7-amino-acid fragment (residues 17 to 23, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, N-acetylated), molecular weight about 889 g/mol, of the 43-amino-acid protein thymosin beta-4 [1]. It is not full-length thymosin beta-4 and not thymosin alpha-1 [1]. 'TB-500' is a common name, not an official drug name; FDA found several salts and derivatives, including different active moieties, sold under the same name [1].
FDA's review says the peptide appears to have first been synthesized in 2003 from thymosin beta-4; a veterinary preparation appeared in 2011, marketed to boost performance in horses and greyhounds [1]. It is sold online as 'research use only' injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157 [1]. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
Can state-licensed pharmacies compound TB-500?
Federal law gives state-licensed pharmacies and physicians three routes for bulk substances: a USP or National Formulary monograph, use as a component of an FDA-approved drug, or appearance on FDA's bulks list [4]. TB-500 has no monograph and is not a component of an approved drug [1]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or on FDA's list for outsourcing facilities (updated March 21, 2025) [2][3][4]. FDA's category 1 policy, which generally says FDA does not intend to act against compounders if conditions are met, does not cover it [2][3][4].
What people on Reddit report
Two comments from one Reddit thread about the July committee votes. Both are opinions on how FDA weighs benefit, safety and industry influence, not personal use reports.
FDA is less concerned about potential benefits and more about safety.Read the source discussion
It really has never been about efficacy or safety - it's all about creating an oligopoly of large industry players and creating extremely high barriers to entry for small innovators.Read the source discussion
What is TB-500's status on FDA's safety-risk page?
TB-500 is listed in the 'nominated but withdrawn' table on FDA's page about bulk substances that may raise significant safety risks (content dated 04/22/2026) [8]. That table holds substances previously in category 2 whose nominators withdrew them [8]. It is not in the active category 2 table [8]. FDA's stated concerns include missing safety information and that injectable peptides may pose immunogenicity risk from aggregation and peptide-related impurities [8]. Removal from category 2 was not a finding that TB-500 is safe [8].
What happened at the July 2026 advisory committee?
FDA's Pharmacy Compounding Advisory Committee reviewed TB-500 on July 23, 2026 and voted in favor of adding it to the bulks list [5][6]. FDA staff had proposed that neither TB-500 free base nor TB-500 acetate be added [1]. The committee's recommendation is advice only and is not binding [5]. TB-500 is not on the list; adding a substance to the list goes through notice-and-comment rulemaking [4].
FDA staff's July 2026 briefing document gave these reasons: TB-500 is not well characterized (inconsistent naming; no impurity, aggregate or endotoxin data); historical use is unclear; there was no evidence of effectiveness for wound healing, the use FDA evaluated; injection carries immunogenicity risk; and FDA-approved wound treatments exist [1].
What does HHS's October 2026 draft policy do?
HHS filed a draft enforcement-discretion policy for compounding with certain peptides on October 28, 2026 (Federal Register document 2026-22192; publication scheduled October 30, 2026; comments due two weeks after publication) [6][7]. It names TB-500 among six peptides, covers TB-500 acetate for subcutaneous or intramuscular injection, and says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the policy's conditions are met [6][7]. Those conditions include a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [6][7].
The draft is not an FDA approval and does not put TB-500 on any list [6]. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public' [6]. HHS may revisit it, for example if a safety signal or product quality issue arises [6]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [6].
Has TB-500 been tested in humans?
FDA searched PubMed, Embase, ClinicalTrials.gov and other sources and found no article in which TB-500 was given to a human, and none of the three papers the nominator cited involved TB-500 in humans [1]. There is no approved dose and no human dosing study of TB-500 [1]. The nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for subcutaneous or intramuscular injection; that is not an approved dose [1].
In an in-vitro scratch-wound test, TB-500 at 50 microgram/mL did not induce wound closure in fibroblast cultures; a shorter metabolite (N-acetylated LKKTE) did show activity in vitro [1]. FDA found no in-vivo animal studies of TB-500 for wound healing [1].
Do thymosin beta-4 studies apply to TB-500?
No. Human trials have tested full-length thymosin beta-4, not TB-500. A phase 1 study of full-length recombinant thymosin beta-4 enrolled 54 healthy volunteers in a single-dose trial and 30 in a multiple-dose trial; adverse events were mild to moderate, with no dose-limiting toxicity or serious adverse events [10]. In a 72-adult dry eye trial, 0.1% thymosin beta-4 drops for 28 days did not significantly change either primary endpoint versus placebo, though some secondary endpoints differed [11]. These results do not show that TB-500 works or is safe [1].
What safety information exists?
FDA's adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and FDA's food and supplement complaint system (January 1, 2004 to March 10, 2025) retrieved two cases about 'blended TB-500 and BPC-157' with no safety assessment [1].
FDA's BPC-157 review describes a 40-year-old woman who used a 'research purposes only' BPC-157 plus TB-500 (5 mg/5 mg) injection product subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, which recurred when she re-tried the product two weeks later [12]. Because the product held two peptides, FDA said it cannot tell whether either caused it [12].
FDA's stated concern for injectable TB-500 is immunogenicity, potentially amplified by peptide aggregation and impurities; FDA found no study of TB-500 immunogenicity or aggregation and no nonclinical toxicity studies [1].
FDA found no human pharmacokinetic or pharmacodynamic data for TB-500 by any route [1]. Animal studies indicate that TB-500 given subcutaneously or intraperitoneally reaches the bloodstream and is broken down into smaller peptides; FDA found no animal studies by intramuscular injection [1].
Is TB-500 banned in sport?
WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, growth factors and growth factor modulators [9]. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [9]. It is on the 2026 List, in force since January 1, 2026, and stays on the 2027 List in a tracked-changes version dated 26 August 2026 [9][13].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is TB-500 FDA-approved?
Is TB-500 on FDA's bulks list?
Did the July 2026 advisory committee make TB-500 legal to compound?
Does the HHS draft policy approve TB-500?
Is TB-500 the same as thymosin beta-4?
Is TB-500 banned in sport?
References
Show all 14 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Reddit participants. Where BPC-157 and TB-500 stand with FDA after the July committee votes (r/bpc_157). Accessed 2026-11-11.